1. Scrip

Novartis' Kesimpta Goes Up Against Roche's Ocrevus In MS

 
• By Jessica Merrill

The anti-CD20 monoclonal antibody was approved by the US FDA for relapsing multiple sclerosis, bringing a new treatment to the crowded therapeutic area – with the benefit of self-administration. 

Businessman and businesswoman armwrestling at the office table, maintaining eye contact, trying to get leadership, fighting for equal rights for women, business competitors in the marketplace
Novartis prepares to face off with Roche in multiple sclerosis with Kesimpta • Source: Shutterstock

Novartis AG's Kesimpta (ofatumumab) could be a fierce new rival to Roche Holding AG's fast-growing Ocrevus (ocrelizumab) in relapsing multiple sclerosis, bringing a similar mechanism of action with monthly self-administration. Kesimpta, a fully human anti-CD20 monoclonal antibody, was approved by the US Food and Drug Administration for relapsing MS on 20 August, after an initial run as Arzerra for chronic lymphocytic leukemia.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas